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Abstract: Sporadic cases of melioidosis have been diagnosed in Myanmar since the disease was
first described in Yangon in 1911. Published and unpublished cases are summarized here, along
with results from environmental and serosurveys. A total of 298 cases have been reported from
seven states or regions between 1911 and 2018, with the majority of these occurring before 1949.
Findings from soil surveys confirm the presence of Burkholderia pseudomallei in the environment in all
three regions examined. The true epidemiology of the disease in Myanmar is unknown. Important
factors contributing to the current gaps in knowledge are lack of awareness among clinicians and
insufficient laboratory diagnostic capacity in many parts of the country. This is likely to have led to
substantial under-reporting.
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1. Introduction and History of Melioidosis in Myanmar
All historical accounts of melioidosis start with Myanmar (formerly Burma), since the disease
was first recognized in 1911 in Rangoon (now Yangon) General Hospital by Alfred Whitmore, a
British pathologist who worked in Burma between 1906 and 1924 [1]. In 1913, Whitmore reported 38
post-mortem cases of a ‘glanders-like disease’, the majority of whom were male and bore stigmata of
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morphine injection. Krishnaswamy, Whitmore’s assistant, reported in 1917 that he had personally seen
more than 200 cases in Rangoon over six years, during which the disease accounted for approximately
one in every 20 autopsies he had conducted [2]. In the ensuing years, reported case numbers in the
country dwindled, and after the end of World War II, the disease disappeared from sight for more than
50 years. This hiatus corresponded firstly with the transition from colonial rule to independence (in
1948) and later with a prolonged period of military rule in Myanmar (1962–2011), during which the
country became closed off from the rest of the world, investment in healthcare slowed, and research
stagnated. Microbiologists working in larger centres inside Myanmar have reported sporadic cases
over the last 20 years, but the true epidemiology of the disease is unknown. Most health facilities in
Myanmar do not have the capacity to identify B. pseudomallei, and most health staff are not aware of
this disease. It is therefore likely that melioidosis is significantly underdiagnosed in Myanmar, and
the projected annual number of cases (more than 6000) and deaths (more than 3000) from a recent
modelling study could well be an accurate reflection of the true situation [3].
2. Review of Melioidosis Cases and Presence of B. pseudomallei in the Country
We searched the PubMed database for cases of melioidosis or evidence of B. pseudomallei using the
following search terms: ((Myanmar) OR Burma)) AND ((melioid*) OR pseudomallei) OR glanders*)).
A separate search was performed for ‘Parotid abscess AND Myanmar’ (no hits). We also consulted
the Myanmar medical literature and the melioidosis global database [4], and contacted consultant
microbiologists in the biggest centres in the country (public sector).
2.1. Results
Evidence for the presence of B. pseudomallei in Myanmar comes from reports of clinical cases,
environmental sampling and serosurveys. Melioidosis has never been diagnosed in animals in
Myanmar although, by analogy with neighbouring countries, infections in animals are almost certainly
occurring undiagnosed.
2.1.1. Clinical Cases
We found a total of 298 published and unpublished cases of melioidosis in Myanmar since 1913
(Table 1). The vast majority (257) were published before the end of 1948. The next report of a case
diagnosed inside the country came about half a century later in 2000 in Mandalay [5]. Of the remaining
cases, several were diagnosed outside Myanmar, and the remainder came from a very small number
of centres. Eighty-five were known to have been culture-confirmed. The report by Krishnaswamy in
which he mentions 200 cases does not state explicitly that these were culture-confirmed; however, given
his position as Whitmore’s assistant and the descriptions of the first 38 cases in which the diagnosis
was confirmed by culture, it is likely that these too were confirmed cases. Of note, only five cases (~2%)
were in females and three in children. A total of 276/298 (93%) cases were diagnosed in patients from
the Yangon area with six from Kayin state, two from Rakhine state, one from Bago region, two from
Ayeyarwady, two from Magway, two from Pyay and four not specified (Table 1 and Figure 1).
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Table 1. Cases of melioidosis reported from Myanmar.
Year of
Report First Author N Cases N Fatalities
N Culture
Confirmed Location in Myanmar Remarks
1913 Whitmore [1] 38 38 38 Yangon Case-series identified post-mortem
1915 Knapp [6] 11 11 1 (remaining NS) Yangon Case-series identified post-mortem
1917 Krishnaswamy [2] ~200 ~200 NS Yangon Cases of ‘morphia injector’s septicaemia’ identifiedpost-mortem
1945 Cox [7] 1 1 1 Not known US Army soldier
1947 Harries [8] 6 2 5 Between Pyay & Yangon (5),Rakhine (1) West African soldiers serving in Myanmar
1948 Sen [9] 1 1 1 Yangon Case identified post-mortem
1979 van der Schaaf [10] 1 1 1 Not known Ex-Royal Netherlands East Indies Army (KNIL) prisoner ofwar. Post-mortem identification
1994 Wilairatana [11] 1 0 1 Not known Myanmar national diagnosed in Bangkok
1999 Kunishima [12,13] 1 0 1 Not known Returned traveler (diagnosed in Japan)
1999 Lee [14] 1 0 1 Yangon Returned traveler (diagnosed in Taiwan)
2000 May Kyi Aung [5] 1 0 1 Mandalay Female
2002 Than Than Aye;referenced in [15] 1 NS NS Yangon Cerebral melioidosis (no information)
2002 Leeuwenburgh [16] 1 0 1 Not known Returned female traveler (diagnosed in Netherlands)
2004 May Kyi Aung [17] 1 1 1 Yangon -
2004 Mo Mo Win [18] 1 0 1 Yangon (Hmawbi) -
2004 Su Su Hlaing [19] 1 0 1 Pyay Concomitant tetanus
2005 Demar [20] 1 0 1 Shwepyitha (Yangon) orKyunbin(Bago) Returned traveler (diagnosed in France)
2008 May Kyi Aung [21] 3 NS 3 Yangon Survey of 133 patients with abscesses in 22 Yangon hospitals
2012 Thae Thae Min [22] 2 0 1 2 Magway Study of 307 patients hospitalised with infectious diseases
2013 Zaw Than Htun [15] 3 NS 3 Yangon (Hmawbi, Thanlyin),Ayeyarwady (Mawkyun) Includes one female
2014 Chu [23] 2 2 2 Thai-Myanmar border (closeto Kayin state) 2 Two fatal cases (one female)
Trop. Med. Infect. Dis. 2018, 3, 28 4 of 9
Table 1. Cont.
Year of
Report First Author N Cases N Fatalities
N Culture
Confirmed Location in Myanmar Remarks
2014 Mar Mar Kyi [24] 1 0 1 Taungoo (Bago) Healthy student with multiple skin abscesses
2015 Mo Mo Win [4] 2 1 3 2 Yangon -
2016 Brummaier [25] 1 0 1 Thai-Myanmar border(close to Kayin state) 2 Ten-year-old boy with subcutaneous abscesses
2016 Mo Mo Win [4] 2 1 2 Yangon -
2016–2017 Shoklo MalariaResearch Unit [4] 3 0 3
Thai-Myanmar border
(close to Kayin state) 2 Includes one child
2017 Mo Mo Win(pers.comm) 7 1 7
Rakhine(1), Ayeyarwady
(1), Yangon (5) Includes one female
2017 Ni Ni Zaw(pers.comm.) 1 NS 1 Mandalay -
2018 Kyaw Myo Tun(pers.comm.) 1 1 1 Yangon -
2018 Mo Mo Win(pers.comm) 1 0
4 1 Yangon -
TOTAL 298
Cases are adult males unless otherwise stated. 1 One patient survived. The other patient was referred to another centre (no outcome recorded). 2 The cases from the Thai-Myanmar border
were diagnosed in a migrant population from Myanmar. 3 Second patient’s outcome not known. 4 Discharged home in pre-terminal condition at request of family; NS = not stated.
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3865 cultures; however, the authors note that bacterial isolation and sub-optimal identification 
techniques may have been one explanation. In addition, the number of cultures requested was low 
relative to the number of admissions in this busy hospital, which exceeds 50,000 per year. 
2.1.2. Serological Evidence for B. pseudomallei in Myanmar 
The gold standard for the diagnosis of melioidosis is bacterial isolation. Serology is difficult to 
interpret in endemic countries due to background positivity rates, but gives some indication of 
population exposure. A cross-sectional sero-survey of 968 migrant workers from Myanmar was 
undertaken in Thailand, close to the western border, in 2005 using a haemagglutination assay [27]. 
The majority of participants (99%) came from Kayin or Mon States and Bago or Yangon Regions. The 
median [IQR] population IHA titre was 1:20 [1:10 to 1:40], with no regional variation observed. Sixty-
nine (7%) participants had a titre ≥1:160, which is a recommended cut-off in Thailand used to support 
Figure 1. Map of Myanmar showing distribution of reported cases (1912–present) by state or region,
categorized by predominant climate type. Each black dot represents a case.
In 2014, the results of all the blood cultures processed by the laboratory of Yangon General
Hospital between 2005 and 2013 were published [26]. B. pseudomallei was not isolated from any of
the 3865 cultures; however, the authors note that bacterial isolation and sub-optimal identification
techniques may have been one explanation. In addition, the number of cultures requested was low
relative to the number of admissions in this busy hospital, which exceeds 50,000 per year.
2.1.2. Serological Evidence for B. pseudomallei in Myanmar
The gold standard for the diagnosis of melioidosis is bacterial isolation. Serology is difficult
to interpret in endemic countries due to background positivity rates, but gives some indication of
population exposure. A cross-sectional sero-survey of 968 migrant workers from Myanmar was
undertaken in Thailand, close to the western border, in 2005 using a haemagglutination assay [27].
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The majority of participants (99%) came from Kayin or Mon States and Bago or Yangon Regions.
The median [IQR] population IHA titre was 1:20 [1:10 to 1:40], with no regional variation observed.
Sixty-nine (7%) participants had a titre ≥1:160, which is a recommended cut-off in Thailand used
to support a clinical diagnosis of melioidosis. Only 8% of surveyed adults were agricultural
workers. Between 2016 and 2017, blood samples were taken for serological testing using a hemolysin
co-regulated protein 1 (Hcp1)-based ELISA from 265 febrile patients presenting to a three outpatient
clinics in a large suburb of Yangon as part of a research study [28]. All patients tested negative (optical
density cut-off 1.16); median [interquartile range] of 0.02 [0.01–0.04] [29].
2.1.3. Evidence from Environmental Surveys
Myanmar has a variable landscape, ranging from the delta region in the south and west, to
the drier central plains, and ending at the Himalayan foothills in the north. Using a mathematical
modelling approach and taking into account known cases, climate and soil type, Myanmar has been
predicted to provide a very suitable environment for the causative bacterium [3]. Results of a farm
survey performed in two townships in Yangon (Thanlyin and Hmawbi) were reported in 2016. From
120 soil samples and 12 water samples collected and processed according to standard microbiological
guidelines for the detection of B. pseudomallei, there were seven positive results (confirmed by molecular
methods) [30]. A national survey is underway by the authors, and preliminary testing has detected the
bacterium by culture of soil samples from townships in Yangon, Kayin and Mon Regions, which is in
agreement with the provenance of some of the reported clinical cases (Table 2). Full results should be
available by the end of 2018.
Table 2. Preliminary results of a soil survey being conducted in Myanmar.
Site Number State or Region Township Total Number ofSamples
Number of
Positive Samples
1 Yangon Hmawbi 1 40 0
2 Yangon Tontay 10 5
3 Yangon Thanlyin 20 0
4 Yangon Kyauktan 20 3
5 Yangon Thone Gwa 20 0
6 Yangon Kha Yan 20 0
7 Yangon Dala 20 0
8 Kayin Kyain Seikgyi 60 0
9 Kayin Myawaddy 140 9
10 Kayin Kawkareik 50 1
11 Kayin Hpa-an 50 1
12 Mon Kyaikhto 40 0
13 Mon Bilin 30 0
14 Mon Thaton 30 0
15 Mon Yae 30 0
16 Mon Thanbyuzayat 40 5
17 Mon Kyaikmaraw 30 2
18 Mon Mawlamyaing 20 0
19 Mon Chaung Sone 20 0
20 Mon Paung 20 0
1 Note: an earlier survey found B. pseudomallei in Hmawbi (see text).
3. Current Recommendations and Availability of Measures Against Melioidosis
Currently, there is no requirement to notify cases of melioidosis in the country. The Ministry of
Health and Sports has set up a national system for communicable disease surveillance and response.
This targets epidemic-prone diseases, specific diseases under national surveillance (DUNS), emerging
infectious diseases, climate-related communicable diseases, and vaccine-preventable diseases, but not
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melioidosis [31]. Under-recognition of the disease is very likely due to a lack of awareness among
health staff, under-utilisation of microbiology services by clinicians and inability of many laboratories
to identify the organism due to poor availability of necessary reagents, as well as a shortage of
microbiologists, particularly in rural areas. There are no standard treatment guidelines for melioidosis,
and the few patients identified are managed on a case by case basis.
4. Awareness of Melioidosis
With the exception of a few ‘enthusiasts’, melioidosis is almost entirely unknown among
healthcare providers. Raising awareness among health staff, clinicians and laboratory staff is therefore
the essential prerequisite to identifying melioidosis patients. When diagnostic and treatment services
for suspected melioidosis cases are established, raising awareness among the population working in
agriculture should follow in high-risk areas. Microbiology in Myanmar is perceived as a diagnostic
rather than a clinical service, and there is limited interaction between microbiologists and clinicians,
which means opportunities to raise awareness are missed. This was highlighted in the report by Hlaing
et al. in 2004 of melioidosis co-infection in a patient with tetanus. A report that B. pseudomallei had
been isolated was duly sent to the ward, but went unnoticed for several days and was acted upon only
when the patient deteriorated.
5. Current and Future Challenges
The burden of melioidosis in Myanmar needs to be defined. The evidence suggests that the
disease is under-recognised and under-reported. While the majority of cases have been reported from
Yangon, evidence from a multicentre abscess survey, routine blood culture surveillance data at a large
centre and a recent serosurvey suggests it may not be a leading cause of sepsis in the greater Yangon
region, despite the fact that it was clearly an important cause of death in the early 20th century [2,21,26].
Reasons for a possible decline in incidence in areas of Yangon where it was common previously are
unclear, although the strong link with injection drug use in the early fatal cases raises the possibility
of contamination of the morphine, which is likely to have originated from Upper Burma [32]. An
alternative explanation is that this group was relatively immunocompromised and more susceptible
to infection following exposure in Yangon itself, and that with increasing urbanization, the risk of
exposure has fallen. It is probable that there are unrecognised melioidosis ‘hot-spots’ elsewhere,
so accurate data across the whole country are needed. Diabetes mellitus, a well-known risk factor
for melioidosis, has moved into the top ten causes of death in the country in the last three years
(http://www.healthdata.org/myanmar), which may drive up case numbers in the future. Important
contributing factors to the current lack of knowledge are a lack of microbiology laboratory diagnostic
capacity, particularly in smaller townships and rural areas, low rates of blood culture requesting, and
lack of awareness of the disease among clinicians. Many laboratories at township level have been
upgraded as part of the National Health Plan, but are not functional due a shortage of microbiologists.
Myanmar has a national reference laboratory (National Health Laboratory), established in 1963, and
a system for disease reporting. Addition of B. pseudomallei to the list of notifiable pathogens might
yield more information on the distribution of cases in the country, but is unlikely to uncover large
numbers until the capacity and usage of diagnostic microbiology increase. Environmental surveys may
be useful to help target scarce resources to augment case-based surveillance in areas where it is likely
to have the highest yield. This should be accompanied by advocacy meetings with state/regional and
township health authorities to raise awareness among clinicians and health providers.
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